Pierre Fabre secures FDA Fast Track for targeted lung cancer drug

The US Food and Drug Administration (FDA) has granted Fast Track designation to Pierre Fabre’s investigational lung cancer drug elticertinib for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations.

The oral tyrosine kinase inhibitor (TKI), also known as PFL-721 and previously STX-721, is being developed for adults whose disease has progressed following platinum-based chemotherapy and amivantamab.

The designation is based on nonclinical findings and preliminary efficacy data from an ongoing Phase 1/2 clinical trial (NCT06043817).

Fast Track status is intended to facilitate the development and review of treatments for serious conditions with unmet medical needs. It provides opportunities for more frequent interaction with the FDA and potential eligibility for rolling review and priority review, subject to the relevant criteria.

Targeting EGFR and HER2 mutations

Elticertinib is an orally administered, irreversible TKI designed to selectively target mutations in epidermal growth factor receptor (EGFR) and ERBB2 (HER2), specifically exon 20 insertions.

These mutations represent a challenging subgroup of NSCLC, a disease in which EGFR mutations are among the most common molecular drivers. EGFR exon 20 insertion mutations account for up to 10% of EGFR-mutated tumours, according to Pierre Fabre.

The drug is being investigated in patients with locally advanced or metastatic disease who have progressed after two treatment approaches, platinum-based chemotherapy and amivantamab.

Eric Ducournau, chief executive officer of Laboratoires Pierre Fabre, said: “This fast-track designation is a first for Laboratoires Pierre Fabre, and a significant milestone that reflects the strength and maturity of our R&D capabilities in oncology.”

The company said the designation also supports its development programme in precision oncology.

Early clinical findings support development

The ongoing Phase 1/2 trial is evaluating elticertinib in patients with locally advanced or metastatic NSCLC carrying EGFR or HER2 exon 20 insertion mutations.

Earlier dose-escalation findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting reported an objective response rate of 54% among 28 patients treated with doses of 360 mg or higher. The disease control rate in this group was 79%.

These preliminary findings provide clinical context for the FDA designation, although further data are needed to establish the drug’s efficacy and safety.

Marie-Andrée Gamache, chief executive officer of Pierre Fabre Pharma, said: “This designation underscores the urgent need for new treatment options for patients with EGFR ex20ins-mutated NSCLC, who still face limited efficacy and significant tolerability challenges with currently available therapies.”

She added that the designation would allow closer engagement with the FDA as the company advances clinical development.

Further clinical development

The Phase 1/2 study is continuing to evaluate elticertinib’s safety, tolerability and antitumour activity, with the aim of establishing an appropriate dose for further development.

The Fast Track designation is the first received by Laboratoires Pierre Fabre and adds to its oncology development programme.

Elticertinib remains investigational and has not been approved for marketing.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox